More Shots on Goal: Heterologous Influenza Prime-Boost Vaccination Decreases the Likelihood of a Negligible Antibody Response to Current or Historical Variants
- 1La Jolla Institute for Immunology
Abstract
Seasonal influenza vaccination only elicits a strong and durable antibody response in a subset of recipients, and prior homologous booster trials have failed to improve on single-dose vaccination. Here, we conducted a phase 4 clinical trial to test if a heterologous prime-boost increases antibody magnitude or breadth as well as reduces the rate of non-responders (ClinicalTrials.gov ID# NCT06567860). Participants received a late-season 2023 inactivated influenza vaccine followed by the 2024 booster four months later containing an updated H3N2 strain alongside unchanged H1N1 and B/Victoria strains, allowing within-subject comparison of heterologous and homologous boosting. The booster vaccination halted or reversed antibody titer waning for all vaccine strains, most notably restoring seroprotective and seroconverting titers for B/Victoria at the cohort-level. Critically, the heterologous booster decreased the rate of non-responders (exhibiting HAI[≤]10 at all time points), with 0% H3N2 non-responders among subjects receiving the prime and boost compared to 29% H1N1 non-responders. A similar pattern held in a larger cohort administering consecutive fall vaccinations, where non-response rate was 20% of H3N2 compared to 37% for H1N1. Across all non-responders that had consistently low titers against the vaccine strains, up to half elicited an antibody response against historical variants, suggesting that immune imprinting partially underlies the non-responder phenotype. Despite differing vaccination timing, late-season priming and standard fall vaccination produced comparable antibody breadth 30 days post-vaccination when cohorts were matched on pre-vaccination titers. These findings suggest that heterologous vaccinations or other multi-strain exposures can reduce the fraction of the population that does not mount an antibody response during an influenza season.
Related
- Evidence for cross-reactivity and protection against Bundibugyo virus disease after heterologous vaccination: a systematic review and meta-analysis
- Determinants of influenza vaccination during the 2021/2022 influenza season in the United States: interactive roles of immunosuppression, cancer diagnosis, and healthcare access barriers
- Immunogenicity, Safety, and Clinical Outcomes Following Homologous and Heterologous SARS-CoV-2 Vaccination Regimens in Patients with Axial Spondyloarthritis and Psoriatic Arthritis: A Prospective Observational Study from the SAFER Cohort.
- A multidisciplinary consensus report on approach to adult influenza in primary care: Diagnosis, treatment, prevention of complications and vaccination
- H5 influenza virus mRNA-lipid nanoparticle (LNP) vaccination elicits adaptive immune responses in Holstein calves
BibTeX
@misc{orsinellirivers2026more,
title = {{More Shots on Goal: Heterologous Influenza Prime-Boost Vaccination Decreases the Likelihood of a Negligible Antibody Response to Current or Historical Variants}},
author = {S. Orsinelli-Rivers and T. M. Ross and T. Einav},
howpublished = {medRxiv},
year = {2026},
month = oct,
doi = {10.64898/2026.10.28.26366744},
url = {https://www.medrxiv.org/content/10.64898/2026.10.28.26366744v1},
note = {CC BY},
}
RIS
TY - UNPB
TI - More Shots on Goal: Heterologous Influenza Prime-Boost Vaccination Decreases the Likelihood of a Negligible Antibody Response to Current or Historical Variants
AU - S. Orsinelli-Rivers
AU - T. M. Ross
AU - T. Einav
PY - 2026
DA - 2026/10/28
PB - medRxiv
DO - 10.64898/2026.10.28.26366744
UR - https://www.medrxiv.org/content/10.64898/2026.10.28.26366744v1
AB - Seasonal influenza vaccination only elicits a strong and durable antibody response in a subset of recipients, and prior homologous booster trials have failed to improve on single-dose vaccination. Here, we conducted a phase 4 clinical trial to test if a heterologous prime-boost increases antibody magnitude or breadth as well as reduces the rate of non-responders (ClinicalTrials.gov ID# NCT06567860). Participants received a late-season 2023 inactivated influenza vaccine followed by the 2024 booster four months later containing an updated H3N2 strain alongside unchanged H1N1 and B/Victoria strains, allowing within-subject comparison of heterologous and homologous boosting. The booster vaccination halted or reversed antibody titer waning for all vaccine strains, most notably restoring seroprotective and seroconverting titers for B/Victoria at the cohort-level. Critically, the heterologous booster decreased the rate of non-responders (exhibiting HAI[≤]10 at all time points), with 0% H3N2 non-responders among subjects receiving the prime and boost compared to 29% H1N1 non-responders. A similar pattern held in a larger cohort administering consecutive fall vaccinations, where non-response rate was 20% of H3N2 compared to 37% for H1N1. Across all non-responders that had consistently low titers against the vaccine strains, up to half elicited an antibody response against historical variants, suggesting that immune imprinting partially underlies the non-responder phenotype. Despite differing vaccination timing, late-season priming and standard fall vaccination produced comparable antibody breadth 30 days post-vaccination when cohorts were matched on pre-vaccination titers. These findings suggest that heterologous vaccinations or other multi-strain exposures can reduce the fraction of the population that does not mount an antibody response during an influenza season.
ER -